Etanercept

Withdrawal and reinitiation of treatment with most biologic agents had minimal impact on efficacy in plaque psoriasis, according to a study.

Enthesitis-related arthritis and a family history of autoimmune disease are key risk factors for inflammatory bowel disease in juvenile idiopathic arthritis, according to data published in Rheumatology.

There is significant variation in the patterns of methotrexate use prior to initiating etanercept in patients with juvenile idiopathic arthritis, according to registry data published in Pediatric Rheumatology.

Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

Approximately 70% of patients with juvenile idiopathic arthritis who are re-treated with etanercept achieve inactive disease status 12 months after receiving the second course, according to data published in Arthritis Research & Therapy.

During a recent event hosted by the Rheumatology Research Foundation, Jeffrey R. Curtis, MD, MS, MPH, said that COVID-19 vaccine boosters could potentially become common among immunocompromised patients.

The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market.

In patients with rheumatoid arthritis who achieve remission with combination therapy and then withdraw either etanercept or methotrexate, monotherapy with the former is superior to the latter for remission maintenance, noted a speaker here.

A U.S. appeals court has ruled in favor of two patents for Amgen’s etanercept against the biosimilar etanercept-szzs from Novartis’ Sandoz, upholding a prior decision validating claims of patent infringement.